Key Points {#FPar1}
==========

There is conflicting preclinical evidence on whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, although both hypotheses are biologically plausible.There is also conflicting evidence on whether the use of ACEI/ARBs affects the prognosis of hospitalised patients with coronavirus disease 2019 (COVID-19).This study found no difference in the risk of mortality associated with prior exposure to ACEIs or ARBs compared with calcium channel blockers.Prior use of ACEIs or ARBs does not modify prognosis in COVID-19 hospitalised patients.

Introduction {#Sec1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the global coronavirus disease 2019 (COVID-19) pandemic that has led to more than 11 million infected patients and almost 540,000 deaths worldwide as at 7 July 2020 \[[@CR1]\]. Italy has been facing one of the largest outbreaks, with around 34,869 deaths currently \[[@CR2]\].

There are several controversial hypotheses on the potentially harmful or beneficial effects of antihypertensive drugs acting on the renin--angiotensin--aldosterone system (RAAS) in COVID-19 \[[@CR3]--[@CR5]\]. These hypotheses are based on the fact that angiotensin-converting enzyme 2 (ACE2) is the receptor binding site for SARS-CoV-2 in the target cell \[[@CR6]\]. In vitro and in vivo studies have demonstrated that ACE inhibitors (ACEIs), as well as angiotensin-II receptor blockers (ARBs), can significantly increase ACE2 expression, thereby facilitating SARS-CoV-2 entry into cells \[[@CR7], [@CR8]\]. Mechanistically, it is possible that ACE2 tissue level changes in response to ACEIs/ARBs in humans, but large clinical studies have not yet confirmed this. However, it has also been found that viral binding to ACE2 decreases its surface expression and prevents angiotensin-II cleavage by ACE to generate angiotensin 1--7, which counterbalances the effect of angiotensin-II signalling through angiotensin receptor type-1 (AT1R). Hence, binding of angiotensin-II to AT1R leads to increased pulmonary vascular permeability, resulting in lung injury \[[@CR9], [@CR10]\]. By blocking AT1R-mediated angiotensin-II adverse effects and increasing ACE2-mediated production of angiotensin 1--7 production, ARBs may counteract this effect and reduce lung damage \[[@CR3]\].

Based on several observational studies (Online Resource 1), there is accumulating evidence that ACEIs and ARBs do not increase the risk of contracting SARS-CoV-2 infection \[[@CR11], [@CR12]\]. On the other hand, conflicting findings regarding the role of ACEIs/ARBs as prognosis modifiers in COVID-19 hospitalised patients have been reported. Published studies on this research question suffer from small sample size and potential residual confounding as they recruited small cohorts of hospitalised patients. Small sample sizes also do not permit sensitivity analyses to be conducted, including dose--effect analyses, which can corroborate the main findings \[[@CR13]--[@CR17]\]. Furthermore, the identification of all covariates related to prior use of chronic medications, as well as comorbidities and a history of prior hospitalisations, may not be accurately evaluated in this setting during a healthcare emergency if data are collected prospectively. The mixed quality of studies investigating whether ACEI/ARB use modifies the prognosis of COVID-19 is seen by the fact that two meta-analyses of observational studies reported contrasting results. One meta-analysis suggested a protective effect of RAAS inhibitors regarding all-cause mortality and critical illness \[[@CR18]\], while the other found no significant association with all-cause mortality \[[@CR19]\]. In addition to the contradictory results, these meta-analyses are problematic because they included an observational study that has since been retracted \[[@CR20]\]. This highlights the need for a large-scale study using appropriate methods to investigate whether prior ACEI/ARB use among persons with COVID-19 improves or worsens the prognosis of persons infected with SARS-CoV-2. Ascertaining the impact of these drugs is essential because it has been suggested that withdrawing RAAS inhibitors and switching to other antihypertensives, such as calcium channel blockers (CCBs), may be beneficial \[[@CR21]\], but there is very little evidence emerging from direct comparisons between these two drug classes \[[@CR11], [@CR14], [@CR22]--[@CR24]\], limiting the usefulness of available studies in clinical practice.

The aim of this population-based Italian retrospective cohort study was to investigate whether ACEI/ARB use prior to hospitalisation increases or decreases the risk of death in a population of over 40,000 patients after they were hospitalised with a diagnosis of COVID-19, identified from a catchment population of 15.2 million persons in the largest study to date.

Methods {#Sec2}
=======

A large-scale, retrospective cohort study was conducted in the Lombardy and Veneto regions and the Reggio Emilia Local Health Unit, covering an underlying population of 15.2 million persons (25% of the Italian population) overall. The protocol was registered in the ENCePP EU-PAS register (EUPAS34541).

Data Source {#Sec3}
-----------

Italy has a National Health System (NHS) that provides universal care. Healthcare services provided are collected using claims databases that have been widely used for clinical and pharmacoepidemiological research \[[@CR25]\]. The data used in this study were recorded through routine data collection, using national data collection systems that were in place prior to the start of the study. The following claims databases were used: hospital admissions, pharmacy claims and copayment exemptions. Pharmacy claims databases were updated as of 31 December 2019, 30 November 2019 and 29 February 2020 in Lombardy, Veneto and Reggio Emilia, respectively. All claims databases date back over 10 years. Hospital admissions in the 10 years preceding COVID-19 hospitalisations, as well as pharmacy claims in the past year, were extracted and used to adjust for confounding. Diagnoses were recorded using the International Classification of Diseases, Clinical Modification, 9th Revision (ICD-CM-9). Pharmacy claims in the last available 3 months prior to COVID-19-related hospitalisation were used to assess antihypertensive exposure. Drug data were recorded using the Anatomical Therapeutic Chemical (ATC) classification system and the National Drug Code (NDC). Copayment exemption databases were used as an additional source to identify diseases that exempt patients from healthcare copay. Using unique anonymised patient identifiers, claims databases were all linked locally to the COVID-19 surveillance database available in each catchment area. This registry contains information (e.g. hospitalisation date, intensive care unit \[ICU\] admission, death) on patients testing positive for SARS-CoV-2 RNA by polymerase chain reaction (PCR) on nasopharyngeal/throat swabs. This database has been used to identify the study population and outcome, and is updated up to 21 April 2020 for Lombardy, and 31 March 2020 for Veneto and Reggio Emilia.

An R-based tool for distributed analyses developed by the Italian National Institute of Health (The ShinISS) was employed by each centre to locally elaborate COVID-19 patient data using a common data model, sharing only a fully anonymised dataset for central analysis, in compliance with EU General Data Protection Regulation regulations.

Study Population {#Sec4}
----------------

All patients aged ≥ 18 years with SARS-CoV-2 infection who were hospitalised from 21 February (date of the first confirmed Italian COVID-19 patient hospitalisation) to 21 April 2020 were identified in the three centres, from the local COVID-19 registry. Admission date was considered the index date (ID). Included patients were followed-up until death (occurring in any setting) or end of the observation period, whichever came first.

Exposure Definition {#Sec5}
-------------------

Exposure of interest was any antihypertensive drug, grouped, using pharmacy claims, into the following mutually exclusive categories: (1) ACEI as monotherapy or fixed combination with other antihypertensive drugs, except for ARBs and CCBs; (2) ACEIs + CCBs as fixed or non-fixed combination; (3) ARBs as monotherapy or fixed combinations with other antihypertensive drugs, except for ACEIs and CCBs; (4) ARBs + CCBs as fixed or non-fixed combinations; (5) CCBs as monotherapy or fixed combination with other antihypertensives, except for ACEIs or ARBs; (6) other antihypertensive drugs, including α2-adrenergic receptor agonists, β-blockers and diuretics; and (7) non-use of any antihypertensive drug (Online Resource 2). A patient was considered exposed to each of the above-mentioned categories if they had at least one pharmacy claim within 3 months prior to the ID. The ACEI, ARB or CCB categories also included a non-fixed combination with drugs from other antihypertensive categories.

Outcomes {#Sec6}
--------

The study outcome was all-cause mortality occurring in or out of hospital, as reported in the COVID-19 registry.

Potential Confounders {#Sec7}
---------------------

In addition to sex, age and catchment area, the following potential confounders were identified: number of hospitalisations in the last 2 years and drug dispensing in the last year; Charlson index (Online Resource 3); cardiocerebrovascular diseases, as well as other acute and chronic diseases; prior use of several chronically used drugs and recent use of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and chloroquine/hydroxychloroquine. Information on diseases was extracted from copayment exemption and hospital discharge databases within the last 10 years of data availability (Online Resource 4). Prior and recent drug use was assessed using pharmacy claims within the last available year and 3 months, respectively (Online Resource 5).

Statistical Analysis {#Sec8}
--------------------

Categorical and continuous variables were described using frequencies with percentages and medians with interquartile ranges (IQRs), respectively. Mortality risk following COVID-19-related hospitalisation was estimated as hazard ratios (HRs) along with 95% confidence intervals (CIs), using a mixed-effect Cox proportional hazard model, comparing ACEIs, ARBs, and other antihypertensives versus CCBs. In an additional analysis, risk was estimated considering non-use of any antihypertensive as the reference category. We modelled catchment area as a random effect. Potential confounders were included in the multivariable model using a stepwise Akaike information criterion (AIC) method. Proportional hazard assumptions were verified on the basis of Schoenfeld residuals, and significance was set at a *p* value \< 0.05. All statistical analyses were performed using STATA version 16 (StataCorp LLC, College Station, TX, USA) and R version 3.6 (The R Foundation for Statistical Computing, Vienna, Austria).

Subgroup and Sensitivity Analyses {#Sec9}
---------------------------------

First, we estimated mortality risk using a propensity-score (PS) matched (1:1) analysis (Online Resources 6 and 7). The standardised differences (SDs) between the exposure groups for each covariate were estimated (Online Resource 8). The nearest-neighbour matching algorithm was used (calliper width 0.05 of the standard deviation of the logit score). Second, to control for potential confounding effects of diuretics and other antihypertensives from the ACEI, ARB and CCB categories, we removed those patients receiving non-fixed combinations of other antihypertensives. Third, we assessed risk estimates only among incident users of antihypertensives (i.e. treatment started within the last 3 months prior to the ID, with no use within 9 months prior). We also explored mortality risk, stratified by any of the diseases listed among the approved treatment indications (hypertension, heart failure, acute myocardial infarction and diabetes mellitus as a proxy of diabetic nephropathy) and cumulative antihypertensive exposure in the last year (categorised by tertile of the total number of defined daily doses (DDDs), with the first tertile being the lowest cumulative exposure and the third tertile being the highest). The number of DDDs was calculated as the dose of drug dispensed multiplied by the quantity dispensed, and dividing this product by the DDD for that drug (obtained from [www.whocc.no/atc_ddd_index/](http://www.whocc.no/atc_ddd_index/)). Mortality risk was also estimated considering only deaths occurring during hospitalisation. As different management of COVID-19 patients and pressure on healthcare system in various regions may affect mortality risk, we stratified analyses by catchment area. Finally, we explored the risk in different calendar periods to account for the centre-specific heterogeneous length of follow-up and changes in COVID-19 management over time.

Results {#Sec10}
=======

Overall, 42,926 hospitalised COVID-19 patients were included in the study (Table [1](#Tab1){ref-type="table"}), with Lombardy accounting for 90.2% of these patients (Online Resource 9). Patients' median age was 69 years (IQR 57--79), with a male-to-female ratio of 1.67. The proportion of COVID-19 patients admitted to the ICU, including antihypertensive users and non-users, during the hospital stay ranged from 7.6% to 18.2% in the three catchment areas. In total, 11,205 (26.1%) of all patients died over a median follow-up of 24 days (IQR 10--35) (Table [2](#Tab2){ref-type="table"}). The total number of patients who were still hospitalised was 8638 (20.1%), while 22,828 (53.2%) were discharged.Table 1Demographic and clinical characteristics of COVID-19 patients included in the study, by exposure group within the last 3 months of observationAll COVID-19 patientsNo anti-HT useARB useACEI useCCB useARB + CCB use (fixed or non-fixed combination)ACEI + CCB use (fixed or non-fixed combination)Other anti-HT use*N* (%)^a^42,92621,974 (51.2)4859 (11.3)4663 (10.9)2178 (5.1)2318 (5.4)2609 (6.1)4068 (9.5)Age, years \[median (IQR)\]69 (57--79)61 (51--73)73 (65--81)75 (65--82)77 (68--83)74 (67--81)75 (66--81)77 (68--84)Age, years \[*n* (%)\] 18--495561 (13.0)5031 (22.9)126 (2.6)114 (2.4)52 (2.4)54 (2.3)70 (2.7)108 (2.7) 50--597172 (16.7)5178 (23.6)531 (10.9)424 (9.1)178 (8.2)238 (10.3)254 (9.7)342 (8.4) 60--698754 (20.4)4621 (21.0)1118 (23.0)894 (19.2)386 (17.7)463 (20.0)548 (21.0)665 (16.3) 70--7910,953 (25.5)3912 (17.8)1626 (33.5)1611 (34.5)675 (31.0)840 (36.2)922 (35.3)1269 (31.2) 80--898880 (20.7)2653 (12.1)1285 (26.4)1392 (29.9)753 (34.6)653 (28.2)703 (26.9)1380 (33.9) ≥ 901606 (3.7)579 (2.6)173 (3.6)228 (4.9)134 (6.2)70 (3.0)112 (4.3)304 (7.5)Sex \[*n* (%)\] Females16,053 (37.4)8371 (38.1)1908 (39.3)1629 (34.9)849 (39.0)785 (33.9)764 (29.3)1677 (41.2)Follow-up days from hospital admission \[median (IQR)\]24 (10--35)26 (13--36)23 (9--35)20 (8--34)20 (7--33)21 (8--34)21 (8--34)18 (7--33)Admitted to ICU \[*n* (%)\]4392 (10.2)2424 (11.0)502 (10.3)411 (8.8)181 (8.3)279 (12.0)307 (11.8)261 (6.4)No. of hospitalisations within the last 12 months \[*n* (%)\] 031,458 (73.3)17,685 (80.5)3530 (72.6)3202 (68.7)1311 (60.2)1608 (69.4)1776 (68.1)2185 (53.7) 16452 (15.0)2722 (12.4)776 (16.0)819 (17.6)409 (18.8)392 (16.9)456 (17.5)826 (20.3) 22600 (6.1)868 (4.0)338 (7.0)328 (7.0)201 (9.2)171 (7.4)211 (8.1)460 (11.3) ≥ 32416 (5.6)699 (3.2)215 (4.4)314 (6.7)257 (11.8)147 (6.3)166 (6.4)597 (14.7)Charlson index \[*n* (%)\] 029,775 (69.4)17,979 (81.8)3225 (66.4)2716 (58.2)1061 (48.7)1416 (61.1)1534 (58.8)1718 (42.2) 1--210,575 (24.6)3463 (15.8)1373 (28.3)1580 (33.9)819 (37.6)724 (31.2)861 (33.0)1645 (40.4) ≥ 32576 (6.0)532 (2.4)261 (5.4)367 (7.9)298 (13.7)178 (7.7)214 (8.2)705 (17.3)No. of pharmacy claims \[median (IQR)\] Within the last 12 months15 (3--36)3 (0--13)27 (14--44)30 (17--49)36 (20--56)36 (22--56)34 (20--53)37 (21--59) Within the last 3 months3 (0--9)0 (0--3)7 (3--11)7 (4--12)8 (5--14)9 (5--14)9 (5--13)9 (5--14)Drug use within the last 12 months \[*n* (%)\] Anticoagulants6743 (15.7)1708 (7.8)937 (19.3)1039 (22.3)523 (24)481 (20.8)529 (20.3)1468 (36.1) Platelet aggregation inhibitors9025 (21.0)1649 (7.5)1429 (29.4)1659 (35.6)826 (37.9)851 (36.7)964 (36.9)1533 (37.7) Lipid-modifying agents12,550 (29.2)2763 (12.6)2132 (43.9)2244 (48.1)978 (44.9)1182 (51.0)1236 (47.4)1859 (45.7) Antiarrhythmics, class I--III1924 (4.5)345 (1.6)329 (6.8)316 (6.8)148 (6.8)177 (7.6)155 (5.9)433 (10.6) Drugs for peptic ulcer16,192 (37.7)4762 (21.7)2374 (48.9)2395 (51.4)1326 (60.9)1233 (53.2)1310 (50.2)2645 (65.0) Drugs for obstructive airway diseases6356 (14.8)2337 (10.6)927 (19.1)781 (16.7)467 (21.4)464 (20.0)411 (15.8)919 (22.6) Antibiotics17,513 (40.8)7372 (33.5)2280 (46.9)2177 (46.7)1119 (51.4)1084 (46.8)1172 (44.9)2190 (53.8) Anti-HIV drugs300 (0.7)136 (0.6)28 (0.6)28 (0.6)24 (1.1)9 (0.4)21 (0.8)48 (1.2) Anti-Parkinson drugs754 (1.8)273 (1.2)88 (1.8)112 (2.4)55 (2.5)38 (1.6)62 (2.4)121 (3.0) Antiepileptics2936 (6.8)1056 (4.8)336 (6.9)401 (8.6)215 (9.9)183 (7.9)209 (8.0)508 (12.5) Antipsychotics1737 (4.0)768 (3.5)172 (3.5)217 (4.7)98 (4.5)76 (3.3)94 (3.6)304 (7.5) Antidepressants5339 (12.4)1899 (8.6)759 (15.6)695 (14.9)374 (17.2)360 (15.5)381 (14.6)830 (20.4)Drug use within the last 3 months \[*n* (%)\] NSAIDs2680 (6.2)993 (4.5)390 (8.0)396 (8.5)159 (7.3)191 (8.2)217 (8.3)307 (7.5) Corticosteroids for systemic use2358 (5.5)806 (3.7)290 (6.0)336 (7.2)193 (8.9)149 (6.4)170 (6.5)400 (9.8) Chloroquine/hydroxychloroquine222 (0.5)69 (0.3)42 (0.9)35 (0.8)13 (0.6)14 (0.6)16 (0.6)28 (0.7) Immunosuppressants695 (1.6)234 (1.1)74 (1.5)93 (2.0)84 (3.9)43 (1.9)53 (2.0)106 (2.6)Comorbidities \[*n* (%)\] Ischaemic heart disease4436 (10.3)710 (3.2)632 (13)903 (19.4)378 (17.4)343 (14.8)432 (16.6)994 (24.4) Atrial fibrillation2899 (6.8)550 (2.5)379 (7.8)485 (10.4)221 (10.1)188 (8.1)229 (8.8)819 (20.1) Heart failure2684 (6.3)447 (2.0)335 (6.9)498 (10.7)229 (10.5)136 (5.9)183 (7.0)831 (20.4) Hypertension5610 (13.1)1097 (5.0)897 (18.5)878 (18.8)552 (25.3)535 (23.1)626 (24.0)960 (23.6) Cerebrovascular diseases3441 (8.0)1041 (4.7)387 (8.0)474 (10.2)305 (14.0)247 (10.7)330 (12.6)623 (15.3) Diabetes mellitus7710 (18.0)1946 (8.9)1234 (25.4)1206 (25.9)608 (27.9)718 (31.0)818 (31.4)1082 (26.6) Liver disease701 (1.6)239 (1.1)75 (1.5)81 (1.7)55 (2.5)41 (1.8)37 (1.4)170 (4.2) Dementia1014 (2.4)444 (2.0)90 (1.9)126 (2.7)70 (3.2)46 (2.0)50 (1.9)183 (4.5) Pneumonia and influenza2737 (6.4)885 (4.0)274 (5.6)353 (7.6)242 (11.1)134 (5.8)197 (7.6)634 (15.6) Renal failure1046 (2.4)255 (1.2)97 (2.0)106 (2.3)158 (7.3)74 (3.2)74 (2.8)270 (6.6) COPD1521 (3.5)389 (1.8)178 (3.7)210 (4.5)162 (7.4)108 (4.7)87 (3.3)376 (9.2) Cancer6446 (15.0)2520 (11.5)780 (16.1)875 (18.8)479 (22.0)409 (17.6)455 (17.4)883 (21.7) Rheumatic diseases375 (0.9)107 (0.5)48 (1.0)51 (1.1)42 (1.9)23 (1.0)18 (0.7)81 (2.0)*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *CCB* calcium channel blocker, *COPD* chronic obstructive pulmonary disease, *anti-HT* antihypertensive drugs (includes α2-adrenergic agonist, diuretics and β-blockers), *ICU* intensive care unit, *IQR* interquartile range, *HIV* human immunodeficiency virus, *NSAIDs* non-steroidal anti-inflammatory drugs^a^We removed 257 patients from the analysis who were concomitantly treated with ARBs and ACEIs (± CCBs or other antihypertensive drugs). The mortality rate of these patients was comparable with that of all other antihypertensive categoriesTable 2Risk factors of all-cause mortality in COVID-19 hospitalised patients, at univariate analysisCovariateNo. of COVID-19 patients \[*n* = 42,926\]No. of deaths (%) \[*n* = 11,205 (26.1)\]Unadjusted HR (95% CI)Centre Lombardy38,71510,569 (27.3)Ref. Reggio Emilia982197 (20.1)0.98 (0.86--1.13) Veneto3229439 (13.6)0.66 (0.60--0.72)Age, years 18--495561141 (2.5)Ref. 50--597172451 (6.3)2.49 (2.06--3.01) 60--6987541484 (17.0)7.04 (5.92--8.37) 70--7910,9533867 (35.3)16.8 (14.2--19.8) 80--8988804343 (48.9)27.6 (23.3--32.6) ≥ 901606919 (57.2)37.5 (31.4--44.8)Sex Male26,8737662 (28.5)Ref. Female16,0533543 (22.1)0.77 (0.74--0.80)No. of hospitalisations within the last 12 months 031,4587181 (22.8)Ref. 164522013 (31.2)1.45 (1.38--1.52) 226001015 (39.0)1.93 (1.80--2.06) ≥ 32416996 (41.2)2.05 (1.92--2.19)Charlson index 029,7755805 (19.5)Ref. 1--210,5754018 (38.0)2.24 (2.15--2.33) ≥ 325761382 (53.6)3.65 (3.44--3.87)Drug use within the last 12 monthsvs. non-use Anticoagulants67432632 (39.0)1.84 (1.76--1.92) Platelet aggregation inhibitors90253775 (41.8)2.22 (2.14--2.31) Lipid-modifying agents12,5504516 (36.0)1.78 (1.72--1.85) Antiarrhythmics, class I and III1924800 (41.6)1.82 (1.70--1.96) Drugs for peptic ulcer16,1925738 (35.4)1.91 (1.84--1.98) Drugs for obstructive airway diseases63562052 (32.3)1.33 (1.27--1.40) Antibiotics17,5135066 (28.9)1.22 (1.17--1.27) Anti-HIV drugs30095 (31.7)1.22 (1.00--1.50) Anti-Parkinson drugs754357 (47.3)2.20 (1.98--2.44) Antiepileptics29361063 (36.2)1.54 (1.45--1.64) Antipsychotics1737750 (43.2)2.01 (1.86--2.16) Antidepressants53391935 (36.2)1.62 (1.54--1.70)Drug use within the last 3 monthsvs. non-use NSAIDs2680781 (29.1)1.15 (1.07--1.23) Corticosteroids for systemic use2358847 (35.9)1.51 (1.41--1.62) Chloroquine/hydroxychloroquine22278 (35.1)1.44 (1.16--1.80) Immunosuppressants695183 (26.3)1.01 (0.87--1.16)Comorbiditiesvs. absence of the disease Ischaemic heart disease44362013 (45.4)2.22 (2.12--2.33) Atrial fibrillation28991323 (45.6)2.19 (2.07--2.32) Heart failure26841416 (52.8)2.74 (2.59--2.90) Hypertension56102396 (42.7)2.11 (2.02--2.21) Cerebrovascular diseases34411554 (45.2)2.23 (2.12--2.36) Diabetes mellitus77103041 (39.4)1.92 (1.84--2.00) Pneumonia and influenza27371313 (48.0)2.34 (2.21--2.48)) Liver disease701286 (40.8)1.73 (1.54--1.94) Dementia1014535 (52.8)2.76 (2.53--3.01) Renal failure1046498 (47.6)2.24 (2.05--2.45) COPD1521699 (46.0)2.10 (1.94--2.27) Cancer64462344 (36.4)1.63 (1.56--1.70) Rheumatic diseases375159 (42.4)1.96 (1.67--2.29)*HR* hazard ratio, *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *HIV* human immunodeficiency virus, *NSAID* non-steroidal anti-inflammatory drug, *Ref.* reference group

Almost 50% of patients had at least one antihypertensive drug claim within 3 months prior to the ID. ARB, ACEI and CCB users accounted for 11.3%, 10.9% and 5.1% of total patients, respectively. The median age of antihypertensive users was 75 years, which was comparable across classes, and was much higher than non-users (61 years; IQR 51--73) (Table [1](#Tab1){ref-type="table"}). Most antihypertensive users were male. CCB and other antihypertensive users more commonly had two or more hospitalisations (21--26%) prior to the ID, and a Charlson index ≥ 3 (13.7--17.3%), compared with ACEI/ARB users. A very high proportion of cardiovascular diseases and drugs among antihypertensive drug users was observed. Categories of other antihypertensives had the most severe pattern of comorbidities. Overall, burden of disease and prior use of other drugs was much higher among antihypertensive users than non-users.

In univariate analyses, advanced age was the strongest predictor of death (Table [2](#Tab2){ref-type="table"}). Male sex, Charlson comorbidity index ≥ 1, and most diseases, especially cardiovascular and neurodegenerative diseases (and related medications), were strongly associated with an increased risk of death. Overall, during the follow-up, the proportion of deaths among antihypertensive users ranged from 31.7 to 40.2% versus 17.1% among non-users (Table [3](#Tab3){ref-type="table"}). In comparison with CCBs, unadjusted analyses showed a statistically significant protective effect for ACEIs and ARBs (also as a fixed-combination with CCB), while an increased risk for other antihypertensive drugs was reported. These statistically significant effects disappeared after adjusting for potential confounders for ACEI users (HR 0.97, 95% CI 0.89--1.06), ARB users (HR 0.98, 95% CI 0.89--1.06), ACEI + CCB users (HR 0.97, 95% CI 0.90--1.05), ARB + CCB users (HR 1.02, 95% CI 0.94--1.11), and other antihypertensives (HR 1.05, 95% CI 0.96--1.14). In comparison with non-use, a statistically significant 2/2.5-fold increased mortality risk was seen for ACEI, ARB and CCB use in unadjusted analysis. In multivariable analysis, this effect almost completely disappeared, although risk estimates were still marginally significant for users of ACEIs (HR 1.10, 95% CI 1.03--1.17), ARBs (HR 1.12, 95% CI 1.05--1.20) and CCBs (HR 1.11, 95% CI 1.03--1.21). Among hypertensive patients only, this effect disappeared (Fig. [1](#Fig1){ref-type="fig"}). The main finding that there is no significantly increased risk of death with ACEI/ARB treatment compared with CCB treatment was confirmed in other sensitivity analyses, including the PS-matched analysis, which included 2031 ARB users (41.9% of all ARB users in the cohort) matched to 2031 CCB users (93.2% of all CCB users in the cohort), and 2094 ACEI users (45.1% of all ACEI users in the cohort) matched to 2094 CCB users (96.1% of all CCB users in the cohort) (Fig. [1](#Fig1){ref-type="fig"}). Results for in-hospital death as the outcome (*n* = 9878) were very similar to death defined for the main analysis, with no significant risk for ARBs or ACEIs compared with CCBs (HR 0.99, 95% CI 0.90--1.07; and HR 0.98, 95% CI 0.90--1.07, respectively). Findings regarding in-hospital death were also similar to the main analysis for ARBs and ACEIs in comparison with the non-use of antihypertensive drugs (HR 1.13, 95% CI 1.06--1.21; and HR 1.12, 95% 1.04--1.20, respectively). There was no trend in mortality risk on increasing cumulative exposure in comparison with CCBs, either for ACEIs or ARBs. Interestingly, there was a non-significant trend for calendar time, where, both for ACEIs and ARBs, there was a non-significant higher risk of death after 11 April 2020. Stratification by catchment area resulted in findings that were likely underpowered for Veneto and Reggio Emilia, although these results are also in line with the main analysis.Table 3Unadjusted and adjusted hazard ratio of all-cause mortality in hospitalised COVID-19 patients in relation to antihypertensive exposure within the last 3 months of observationNo of deaths (% of total users)No. of total usersUnadjusted HR (95% CI)Adjusted HR^a^ (95% CI)ARBs1540 (31.7)48590.79 (0.72--0.86)0.98 (0.89--1.06)ACEIs1606 (34.4)46630.89 (0.81--0.96)0.97 (0.89--1.06)Other anti-HT drugs1634 (40.2)40681.08 (1.00--1.18)1.05 (0.96--1.14)ARBs + CCBs^b^2399 (33.4)71770.84 (0.77--0.91)1.02 (0.94--1.11)ACEIs + CCBs^c^2496 (34.3)72720.88 (0.82--0.96)0.97 (0.90--1.05)CCBs822 (37.7)2178Reference categoryReference categoryARBs1540 (31.7)48591.99 (1.87--2.11)1.12 (1.05--1.20)ACEIs1606 (34.4)46632.24 (2.11--2.37)1.10 (1.03--1.17)CCBs822 (37.7)21782.52 (2.34--2.72)1.11 (1.03--1.21)ARBs + CCBs^d^859 (37.1)23182.40 (2.23--2.58)1.29 (1.19--1.40)ACEIs + CCBs^e^890 (34.1)26092.21 (2.05--2.37)1.13 (1.04--1.22)Other anti-HT drugs1634 (40.2)40682.73 (2.58--2.90)1.17 (1.09--1.25)Non-use of any anti-HT drug3766 (17.1)21,974Reference categoryReference category*ACEIs* ACE inhibitors, *ARBs* angiotensin receptor blockers, *CCBs* calcium channel blockers, *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *anti-HT* antihypertensive drugs (α2-adrenergic agonist, diuretics, and β-blockers), *HR* hazard ratio, *HIV* human immunodeficiency virus, *NSAIDs* non-steroidal anti-inflammatory drugs^a^Cox proportional regression model (stepwise forward based on Akaike's information criterion) adjusted for the following eligible variables: centre, age, sex, Charlson index, number of drug dispensings, drugs for peptic ulcer, anticoagulants, antiplatelet drugs, lipid-modifying agents, antiarrhythmic drugs, drugs for obstructive airway diseases, antibiotics, anti-HIV drugs, anti-Parkinson drugs, antiepileptic drugs, antipsychotics, antidepressants, NSAIDS, corticosteroids, chloroquine/hydroxychloroquine, immunosuppressants, pneumonia and influenza, ischaemic heart disease, atrial fibrillation, heart failure, hypertension, cerebrovascular diseases, diabetes mellitus, liver disease, dementia, renal failure, COPD, cancer, and rheumatic diseases^b^ARBs as monotherapy or fixed combination with other HT drugs, except for ACEIs and CCBs or ARBs + CCBs as fixed combination^c^ACEIs as monotherapy or fixed combination with other HT drugs, except for ARBs and CCBs or ACEIs + CCBs as fixed combination^d^ARBs + CCBs as fixed combination^e^ACEIs + CCBs as fixed combinationFig. 1Sensitivity and subgroup analyses of all-cause mortality risk in hospitalised COVID-19 patients in association with ACEIs/ARBs vs. CCBs (or non-use). *AMI* acute myocardial infarction, *ACEIs* angiotensin-converting enzyme inhibitors, *ARBs* angiotensin receptor blocker, *CCB*s calcium channel blockers, *CI* confidence interval, *AH* antihypertensive drugs (α2-adrenergic agonist, diuretics, and β-blockers, *NSAIDs* non-steroidal anti-inflammatory drugs, *COPD* chronic obstructive pulmonary disease, *LO* Lombardy region, *HIV* human immunodeficiency virus, *HR* hazard ratio, *RE* Reggio Emilia LHU, *VE* Veneto region, *DDDs* defined daily doses. \^Cox proportional regression model (stepwise forward based on Akaike's information criterion) adjusted for the following eligible variables: centre, age, sex, Charlson index, number of drug dispensings, drugs for peptic ulcer, anticoagulants, antiplatelet drugs, lipid-modifying agents, antiarrhythmics, drugs for obstructive airway diseases, antibiotics, anti-HIV drugs, anti-Parkinson drugs, antiepileptics, antipsychotics, antidepressants, NSAIDS, corticosteroids, chloroquine/hydroxychloroquine, immunosuppressants, pneumonia and influenza, ischaemic heart disease, atrial fibrillation, heart failure, hypertension, cerebrovascular diseases, diabetes mellitus, liver disease, dementia, renal failure, COPD, cancer, and rheumatic diseases. \*Propensity-score matched Cox regression model. \*\*ARB: 1° tertile: upper tertile of number of DDDs in the last year: \< 224; 2° tertile: intermediate tertile: 224--419; 3° tertile: low tertile: ≥ 420; ACEI: 1° tertile: upper tertile \< 280; 2° tertile: intermediate tertile: 280--615; 3° tertile: low tertile: ≥ 616. \*\*\*Only the Lombardy region. \*\*\*\*Cox regression model adjusted by propensity score

Discussion {#Sec11}
==========

The present study is the largest to date to investigate the safety of ACEIs and ARBs in persons with COVID-19. The main finding of this study was that prior exposure to ACEIs/ARBs among new users of these drugs neither worsened nor improved the prognosis of hospitalised COVID-19 patients in terms of all-cause mortality compared with CCBs. The sample size of the study allowed us to conduct several supporting and sensitivity analyses. We observed no increased risk of death among ACEI or ARB users having the highest drug cumulative exposure (upper tertile of DDDs) within 1 year prior to the ID, compared with CCB use. This finding was confirmed in several supporting and sensitivity analyses, using the PS matching approach or changing exposure and outcome definitions.

When considering non-use as a comparator, the 2/2.5-fold increased risk of death with all antihypertensive drugs in unadjusted analyses almost completely disappeared after controlling for confounders, yielding a marginally significant 10--15% increased mortality risk, likely attributable to residual confounding by indication. Accordingly, in hypertensive patients specifically, no statistically significant difference in risk for ACEI/ARB use versus non-use of antihypertensives was observed. This finding is in line with three small Chinese retrospective studies demonstrating that in-hospital exposure to ACEIs/ARBs in hypertensive COVID-19 patients was not associated with increased mortality \[[@CR14], [@CR24]\]. Larger studies have also shown a lack of association between these drug classes and severe COVID-19, as measured by outcomes such as intensive care or death \[[@CR11], [@CR26]\].

The studies reporting a potentially protective effect were either not published in peer-reviewed scientific journals \[[@CR14], [@CR27]\], were not full research papers but letters with limited detail \[[@CR28]\], or were retracted \[[@CR29]\]. While previous observational studies provided preliminary evidence that there is no additional risk of mortality with RAAS inhibitors compared with other antihypertensive drugs in COVID-19 patients, estimates from this large-scale study, based on extensive adjustment for potential confounders and numerous sensitivity analyses, confirm that there is no increase in risk. In addition, we showed that there is no protective effect of ACEIs/ARBs, as previously reported in a meta-analysis of observational studies \[[@CR18]\] that were mainly conducted through retrospective assessment of small cohorts of hospitalised patients with COVID-19. The present study is based on a much larger study population, more extensive adjustment for confounding and a larger battery of sensitivity analyses.

This study has several strengths. First, we performed the study using a large multiple database network with quasi real-time data access for over 40,000 COVID-19 hospitalised patients from three regions, each of which was heavily affected by SARS-CoV-2 infection. The data used in the present study were collected while the pandemic was at its peak, increasing the significance of our findings. While an observational study set in Lombardy has already been published \[[@CR11]\], the present study has over 1 month of additional data, with a population size that is approximately seven times as large. The estimated overlap between our hospitalised population and that of Mancia et al. is approximately 6%, with the total number of ACEI/ARB users being around 720 \[[@CR11]\]. Moreover, the study design by Mancia et al. was not intended to evaluate how RAAS inhibitors could affect the prognosis among persons with COVID-19, and therefore may not be very informative in this regard. Second, the use of the COVID-19 patient registry, which is maintained by the Italian NHS and updated daily, leverages accurately collected data on patients testing positive for SARS-CoV-2 RNA by PCR on nasopharyngeal/throat swabs. Third, this is the largest cohort of COVID-19 patients, at least in Europe, that has been analysed at a population-based level to date. This large sample size allowed us to perform a number of sensitivity/subgroup analyses, thus increasing the robustness of study findings. A variety of approaches were used to control for confounding, including stratification by comorbidity and cumulative exposure, as well as the use of PSs. We were able to adjust for a very large number of potential confounders by leveraging Italian NHS claims databases that have been used widely, by linking them at the individual patient level to the COVID-19 surveillance registry. Regarding the exposure, in the present study we have distinguished between ACEI and ARB use as monotherapy or combination therapy, which has not always been done in previous studies \[[@CR14], [@CR23], [@CR24], [@CR30]\]. We selected a comparator, CCB use, which is a therapeutic alternative to ACEI/ARB use, making our findings relevant to decision making in clinical practice. This has also not always been done in previous studies \[[@CR14], [@CR23], [@CR24], [@CR30]\]. Finally, to our knowledge, the present study is the only study that has investigated the dose--effect response on the risks associated with ACEI/ARB use. Dose--effect analyses are essential to demonstrate the biological plausibility of a hypothesised drug-related risk. A different outcome definition was also applied, i.e. in-hospital mortality, in addition to the primary outcome definition, i.e. all-cause mortality in any setting. This not only further confirms the main findings but also shows the lack of competing risks.

Nevertheless, some limitations warrant caution. We had access to pharmacy claims of COVID-19 patients up to 29 February 2020, 31 December 2019 and 30 November 2019 in Reggio Emilia, Lombardy and Veneto, respectively. As such, we may have misclassified exposure, especially in Lombardy and Veneto, if antihypertensive users withdrew/switched therapies due to concerns about SARS-COV-2 infection in the period immediately preceding COVID-19 hospitalisation. However, in the trimester prior to COVID-19 hospitalisation in Reggio Emilia, only 1.5% and 1.4% of ACEI and ARB users, respectively, switched to CCBs. We have no reason to believe that this trend was different in the other two Northern Italian catchment areas considered. COVID-19 patients with the lowest cumulative exposure to antihypertensive drugs in the past year (as a proxy of low adherence), who may be more likely to withdraw therapy, were not associated with higher death risk, compared with CCBs. We did not have information on risk factors for death in COVID-19 patients such as obesity and smoking; however, we adjusted the analysis for comorbidities strictly correlated to these variables (e.g. diabetes mellitus and chronic obstructive pulmonary disease), thus potentially accounting for their confounding effect. We explored the exposure status only in an outpatient setting, and we do not know if antihypertensive drugs were continued during hospital stay. Finally, some comorbidities that are not likely to be the cause of hospitalisation, especially chronic conditions such as hypertension and diabetes, may be underestimated as they were mainly identified from hospital discharge diagnoses. Another limitation is that there may be potential bias in our cohort of hospitalised patients as the criteria for hospital admission are not defined and may depend on several factors, including severity, availability of hospital beds, etc., that are likely to vary from hospital to hospital. Nevertheless, a case--control study conducted in Italy has shown that there is no difference between ACEI or ARB use and the risk of hospitalisation among COVID-19 patients \[[@CR11]\].

Conclusion {#Sec12}
==========

This large Italian population-based cohort study demonstrated that prior exposure to ACEIs and ARBs is not associated with either an increased or decreased risk of all-cause mortality in hospitalised COVID-19, in comparison with CCBs. This finding strengthens recommendations from international regulatory drug agencies and scientific societies about not withdrawing ACEI/ARB therapies or switching to other antihypertensive drugs for the prevention of COVID-19-related death. Furthermore, this study shows that real-world evidence generation during healthcare emergencies may rapidly confirm or refute hypotheses derived from in vitro studies.
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